Print  |  Close

Study of Biomarker-Based Treatment of Acute Myeloid Leukemia


Active: Yes
Cancer Type: Cancer-Related Syndrome
Leukemia
Myelodysplastic Syndromes (MDS)
NCT ID: NCT03013998
Trial Phases: Phase I
Phase II
Protocol IDs: BAML-16-001 (primary)
NCI-2017-00278
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Beat AML, LLC
NCI Full Details: http://clinicaltrials.gov/show/NCT03013998

Summary

This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic
screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol
(BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which
sub-study, within this protocol, a participant will be assigned to evaluate investigational
therapies or combinations with the ultimate goal of advancing new targeted therapies for
approval. The study also includes a marker negative sub-study which will include all screened
patients not eligible for any of the biomarker-driven sub-studies.

Treatment Sites in Georgia

Emory University Hospital - Atlanta
1364 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.